Ampreloxetine
Orthostatic Hypotension
Theravance BiopharmaSmall moleculePhase 2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 30/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Orthostatic Hypotension cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Droxidopa Alberto Espay, MD, MSc | Phase 4 | BBB |
Midodrine Vanderbilt University Medical Center | Phase 2 | BB |
LEVODOPA University of Utah | Phase 2/3 | B |
Astragalus Fujian Medical University Union Hospital | Phase 2 | CCC |
DOMPERIDONE Royal Brisbane and Women's Hospital | Phase 1 | CC |
FLUDROCORTISONE Royal Brisbane and Women's Hospital | Phase 1 | CC |
TRIMETAPHAN Vanderbilt University | Phase 1 | CC |
Same molecule, other indications
Ampreloxetine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →